Abstract
Introduction/Background*Rucaparib is a PARP-1/2/3 inhibitor approved for the treatment of high-grade ovarian cancer (HGOC). In ARIEL3, rucaparib improved PFS as maintenance therapy for platinum (Pt)-sensitive recurrent OC. Study 10, ARIEL2,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have